The specific impact of DTG, BIC and TAF on weight gain/obesity in PWH is confirmed in
different populations independently of the weight limiting effect of EFV and TDF. ART-linked …

Clinical consequences of weight gain during treatment for HI... : Current Opinion in HIV and
AIDS Clinical consequences of weight gain during treatment for HIV infection : Current Opinion …

Objective Multiple strategies have been utilised to reduce the incidence of HIV, including
PrEP and rapid antiretroviral therapy initiation. The study objectives were to evaluate the …

In 2019, the publication of 2 randomized clinical trials conducted in sub-Saharan Africa sent
a potential safety signal by reporting greater weight gain with dolutegravir than with …

Intersections between HIV and obesity in emerging economies : Current Opinion in HIV and
AIDS Intersections between HIV and obesity in emerging economies : Current Opinion in HIV …

HIV infection has been controlled only since the introduction of triple therapy in 1996,
combining, as antiretroviral agents, two nucleoside reverse transcriptase inhibitors (NRTIs) …

In 2022, approximately 29 million people living with HIV were accessing antiretroviral
therapy (ART) globally [1]. For first-line treatment, the WHO recommends TDF/XTC/DTG: the …

Introduction Integrase strand transfer inhibitor-based regimens (eg, containing dolutegravir
[DTG]) are associated with weight/body mass index (BMI) increases among people living …

Most industry-sponsored clinical trials of HIV treatment (ART) have enrolled young and
middle-aged adults. However, as a group, people with HIV are now living longer thanks to …

In 2022, approximately 29 million people living with HIV were accessing antiretroviral
therapy (ART) globally [1]. For first-line treatment, the WHO recommends TDF/XTC/DTG: the …